skip to content
Therapies for clinically localized prostate cancer : update of a 2008 systematic review Preview this item
ClosePreview this item
Checking...

Therapies for clinically localized prostate cancer : update of a 2008 systematic review

Author: Fang Sun, M.D.; United States. Agency for Healthcare Research and Quality,; ECRI Institute-Penn Medicine Evidence-based Practice Center,; Effective Health Care Program (U.S.); Minnesota Evidence-based Practice Center.
Publisher: Rockville, MD : Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, December 2014.
Series: Comparative effectiveness review, no. 146.; AHRQ publication, no. 15-EHC004-EF.
Edition/Format:   eBook : Document : National government publication : English
Summary:
OBJECTIVE: To comprehensively update a 2008 systematic review on treatments for cancer confined to the prostate gland, which is the definition of clinically localized disease. DATA SOURCES: We searched MEDLINE(r), PreMEDLINE, Embase(r), the Cochrane Library, the Database of Abstracts of Reviews of Effects, the Health Technology Assessment Database, gray literature, and the U.K. National Health Service Economic  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Review
Material Type: Document, Government publication, National government publication, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Fang Sun, M.D.; United States. Agency for Healthcare Research and Quality,; ECRI Institute-Penn Medicine Evidence-based Practice Center,; Effective Health Care Program (U.S.); Minnesota Evidence-based Practice Center.
OCLC Number: 910948345
Notes: Title from PDF title page.
Preceded by Comparative effectiveness of therapies for clinically localized prostate cancer / prepared by Minnesota Evidence-based Practice Center ; investigators, Timothy J. Wilt [and others]. 2008.
Description: 1 online resource (1 PDF file (various pagings)).
Series Title: Comparative effectiveness review, no. 146.; AHRQ publication, no. 15-EHC004-EF.
Responsibility: investigators, Fang Sun, Olu Oyesanmi, Joann Fontanarosa, James Reston, Thomas Guzzo, Karen Schoelles.

Abstract:

OBJECTIVE: To comprehensively update a 2008 systematic review on treatments for cancer confined to the prostate gland, which is the definition of clinically localized disease. DATA SOURCES: We searched MEDLINE(r), PreMEDLINE, Embase(r), the Cochrane Library, the Database of Abstracts of Reviews of Effects, the Health Technology Assessment Database, gray literature, and the U.K. National Health Service Economic Evaluation Database for reports published from January 1, 2007, through March 7, 2014. REVIEW METHODS: We synthesized evidence from randomized controlled trials (RCTs) and nonrandomized comparative studies published in English that evaluated treatments and reported clinical or biochemical outcomes in patients with clinically localized prostate cancer. RESULTS: Eight RCTs and 44 nonrandomized comparative studies evaluating numerous treatment options met inclusion criteria. However, because most comparisons were represented by only one or two studies, the strength of evidence (SOE) was insufficient for the majority of comparisons. Two RCTs, the Scandinavian Prostate Cancer Group-4 (SPCG-4) and the Prostate Intervention Versus Observation Trial (PIVOT) compared radical prostatectomy (RP) and watchful waiting (WW) in localized prostate cancer patients. No meta-analysis was done because of the heterogeneity of included patients. While the SPCG-4 study found that RP reduced prostate cancer-specific mortality at 12 and 15 years, the PIVOT trial found no statistically significant difference at 12 years. The SPCG-4 study found that RP reduced all-cause mortality at 15 years, but neither the SPCG-4 nor the PIVOT trial found any significant difference at 12 years. The SOE for these outcomes was insufficient. However, both trials found significant reductions in progression to metastases in the RP group compared with the WW group (SOE: moderate). In the SPCG-4 trial, subgroup analyses showed reduced all-cause mortality among patients younger than 65 years and among patients with low tumor risk. In the PIVOT, reduced all-cause mortality was identified among men with prostate-specific antigen>10 ng/mL and among men with intermediate tumor risk. One RCT that compared three-dimensional conformal radiotherapy (3D-CRT) with 3D-CRT plus androgen-deprivation therapy (ADT) reported an improvement in overall survival and prostate cancer-specific mortality among men who received combined therapy (SOE: low). Six nonrandomized comparison studies reported that all-cause and prostate cancer-specific mortality was lower in patients treated with RP than in patients treated with external beam radiation therapy (SOE: low). The definition and severity of adverse events varied greatly across studies. Adverse events such as urinary incontinence and erectile dysfunction were reported mostly among men who underwent RP. Additionally, adverse events such as genitourinary toxicity, gastrointestinal toxicity, and erectile dysfunction were reported among men who received radiation therapy. CONCLUSIONS: This systematic review update found that the evidence for most treatment comparisons is largely inadequate to determine comparative risks and benefits of therapies for clinically localized prostate cancer. This conclusion is similar to that of the 2008 review, which found that no single therapy can be considered the preferred treatment for localized prostate cancer because of limitations in the body of evidence as well as the likely tradeoffs a patient must make between estimated treatment effectiveness, necessity, and adverse effects. Although limited evidence appears to favor surgery over WW or external beam radiotherapy, or favors 3D-CRT plus ADT over 3D-CRT alone, the patients most likely to benefit and the applicability of these study findings to contemporary patients and practice remain uncertain. More RCTs and better designed observational studies that can control for many of the known and unknown confounding factors that can affect long-term outcomes are needed to evaluate comparative risks and benefits of therapies for clinically localized prostate cancer.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/910948345> # Therapies for clinically localized prostate cancer : update of a 2008 systematic review
    a schema:CreativeWork, schema:Book, schema:MediaObject ;
    library:oclcnum "910948345" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/mdu> ;
    rdfs:seeAlso <http://experiment.worldcat.org/entity/work/data/2546957996#CreativeWork/comparative_effectiveness_of_therapies_for_clinically_localized_prostate_cancer> ; # Comparative effectiveness of therapies for clinically localized prostate cancer.
    schema:about <http://experiment.worldcat.org/entity/work/data/2546957996#Topic/treatment_outcome> ; # Treatment Outcome
    schema:about <http://experiment.worldcat.org/entity/work/data/2546957996#Topic/prostatic_neoplasms_therapy> ; # Prostatic Neoplasms--therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/2546957996#Topic/risk_assessment> ; # Risk Assessment
    schema:about <http://experiment.worldcat.org/entity/work/data/2546957996#Topic/comparative_effectiveness_research> ; # Comparative Effectiveness Research
    schema:about <http://experiment.worldcat.org/entity/work/data/2546957996#Topic/prostatic_neoplasms_prevention_&_control> ; # Prostatic Neoplasms--prevention & control
    schema:author <http://experiment.worldcat.org/entity/work/data/2546957996#Person/sun_fang_m_d> ; # M.D. Fang Sun
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/2546957996#Organization/ecri_institute_penn_medicine_evidence_based_practice_center> ; # ECRI Institute-Penn Medicine Evidence-based Practice Center,
    schema:contributor <http://experiment.worldcat.org/entity/work/data/2546957996#Organization/united_states_agency_for_healthcare_research_and_quality> ; # United States. Agency for Healthcare Research and Quality,
    schema:contributor <http://experiment.worldcat.org/entity/work/data/2546957996#Organization/minnesota_evidence_based_practice_center> ; # Minnesota Evidence-based Practice Center.
    schema:contributor <http://experiment.worldcat.org/entity/work/data/2546957996#Organization/effective_health_care_program_u_s> ; # Effective Health Care Program (U.S.)
    schema:datePublished "2014" ;
    schema:description "OBJECTIVE: To comprehensively update a 2008 systematic review on treatments for cancer confined to the prostate gland, which is the definition of clinically localized disease. DATA SOURCES: We searched MEDLINE(r), PreMEDLINE, Embase(r), the Cochrane Library, the Database of Abstracts of Reviews of Effects, the Health Technology Assessment Database, gray literature, and the U.K. National Health Service Economic Evaluation Database for reports published from January 1, 2007, through March 7, 2014. REVIEW METHODS: We synthesized evidence from randomized controlled trials (RCTs) and nonrandomized comparative studies published in English that evaluated treatments and reported clinical or biochemical outcomes in patients with clinically localized prostate cancer. RESULTS: Eight RCTs and 44 nonrandomized comparative studies evaluating numerous treatment options met inclusion criteria. However, because most comparisons were represented by only one or two studies, the strength of evidence (SOE) was insufficient for the majority of comparisons. Two RCTs, the Scandinavian Prostate Cancer Group-4 (SPCG-4) and the Prostate Intervention Versus Observation Trial (PIVOT) compared radical prostatectomy (RP) and watchful waiting (WW) in localized prostate cancer patients. No meta-analysis was done because of the heterogeneity of included patients. While the SPCG-4 study found that RP reduced prostate cancer-specific mortality at 12 and 15 years, the PIVOT trial found no statistically significant difference at 12 years. The SPCG-4 study found that RP reduced all-cause mortality at 15 years, but neither the SPCG-4 nor the PIVOT trial found any significant difference at 12 years. The SOE for these outcomes was insufficient. However, both trials found significant reductions in progression to metastases in the RP group compared with the WW group (SOE: moderate). In the SPCG-4 trial, subgroup analyses showed reduced all-cause mortality among patients younger than 65 years and among patients with low tumor risk. In the PIVOT, reduced all-cause mortality was identified among men with prostate-specific antigen>10 ng/mL and among men with intermediate tumor risk. One RCT that compared three-dimensional conformal radiotherapy (3D-CRT) with 3D-CRT plus androgen-deprivation therapy (ADT) reported an improvement in overall survival and prostate cancer-specific mortality among men who received combined therapy (SOE: low). Six nonrandomized comparison studies reported that all-cause and prostate cancer-specific mortality was lower in patients treated with RP than in patients treated with external beam radiation therapy (SOE: low). The definition and severity of adverse events varied greatly across studies. Adverse events such as urinary incontinence and erectile dysfunction were reported mostly among men who underwent RP. Additionally, adverse events such as genitourinary toxicity, gastrointestinal toxicity, and erectile dysfunction were reported among men who received radiation therapy. CONCLUSIONS: This systematic review update found that the evidence for most treatment comparisons is largely inadequate to determine comparative risks and benefits of therapies for clinically localized prostate cancer. This conclusion is similar to that of the 2008 review, which found that no single therapy can be considered the preferred treatment for localized prostate cancer because of limitations in the body of evidence as well as the likely tradeoffs a patient must make between estimated treatment effectiveness, necessity, and adverse effects. Although limited evidence appears to favor surgery over WW or external beam radiotherapy, or favors 3D-CRT plus ADT over 3D-CRT alone, the patients most likely to benefit and the applicability of these study findings to contemporary patients and practice remain uncertain. More RCTs and better designed observational studies that can control for many of the known and unknown confounding factors that can affect long-term outcomes are needed to evaluate comparative risks and benefits of therapies for clinically localized prostate cancer."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/2546957996> ;
    schema:genre "National government publication"@en ;
    schema:genre "Review"@en ;
    schema:genre "Government publication"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/2546957996#Series/ahrq_publication> ; # AHRQ publication ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/2546957996#Series/comparative_effectiveness_review> ; # Comparative effectiveness review ;
    schema:name "Therapies for clinically localized prostate cancer : update of a 2008 systematic review"@en ;
    schema:productID "910948345" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK269320/> ;
    schema:url <https://www.ncbi.nlm.nih.gov/books/NBK269320> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/910948345> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/2546957996#CreativeWork/comparative_effectiveness_of_therapies_for_clinically_localized_prostate_cancer> # Comparative effectiveness of therapies for clinically localized prostate cancer.
    a schema:CreativeWork ;
    schema:creator <http://experiment.worldcat.org/entity/work/data/2546957996#Organization/minnesota_evidence_based_practice_center> ; # Minnesota Evidence-based Practice Center.
    schema:name "Comparative effectiveness of therapies for clinically localized prostate cancer." ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Organization/ecri_institute_penn_medicine_evidence_based_practice_center> # ECRI Institute-Penn Medicine Evidence-based Practice Center,
    a schema:Organization ;
    schema:name "ECRI Institute-Penn Medicine Evidence-based Practice Center," ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Organization/effective_health_care_program_u_s> # Effective Health Care Program (U.S.)
    a schema:Organization ;
    schema:name "Effective Health Care Program (U.S.)" ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Organization/minnesota_evidence_based_practice_center> # Minnesota Evidence-based Practice Center.
    a schema:Organization ;
    schema:name "Minnesota Evidence-based Practice Center." ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Organization/united_states_agency_for_healthcare_research_and_quality> # United States. Agency for Healthcare Research and Quality,
    a schema:Organization ;
    schema:name "United States. Agency for Healthcare Research and Quality," ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Person/sun_fang_m_d> # M.D. Fang Sun
    a schema:Person ;
    schema:familyName "Sun" ;
    schema:givenName "Fang" ;
    schema:name "M.D. Fang Sun" ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Series/ahrq_publication> # AHRQ publication ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/910948345> ; # Therapies for clinically localized prostate cancer : update of a 2008 systematic review
    schema:name "AHRQ publication ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Series/comparative_effectiveness_review> # Comparative effectiveness review ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/910948345> ; # Therapies for clinically localized prostate cancer : update of a 2008 systematic review
    schema:name "Comparative effectiveness review ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Topic/comparative_effectiveness_research> # Comparative Effectiveness Research
    a schema:Intangible ;
    schema:name "Comparative Effectiveness Research"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Topic/prostatic_neoplasms_prevention_&_control> # Prostatic Neoplasms--prevention & control
    a schema:Intangible ;
    schema:name "Prostatic Neoplasms--prevention & control"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Topic/prostatic_neoplasms_therapy> # Prostatic Neoplasms--therapy
    a schema:Intangible ;
    schema:name "Prostatic Neoplasms--therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2546957996#Topic/treatment_outcome> # Treatment Outcome
    a schema:Intangible ;
    schema:name "Treatment Outcome"@en ;
    .

<http://www.worldcat.org/title/-/oclc/910948345>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/910948345> ; # Therapies for clinically localized prostate cancer : update of a 2008 systematic review
    schema:dateModified "2018-01-09" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.